National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 2 of 1999)

Overview

The National Health Act 1953 was enacted by the Australian Parliament to establish a framework for the provision of health services and the regulation of health-related activities. This legislation was introduced to address the need for a cohesive national approach to health care, ensuring that services are accessible and regulated in a manner that promotes the health and well-being of the Australian population. The Act includes provisions for the Pharmaceutical Benefits Scheme, among other things, which facilitates access to essential medications at subsidised rates. In line with its policy objective to continually review and adjust the list of subsidised medications, the Act allows for the declaration of certain drugs and preparations that no longer qualify for subsidy under Part VII. This ensures that resources are allocated efficiently and that the scheme remains sustainable and responsive to the evolving needs of the community. The declaration process is governed by subsection 85(2AA) of the Act, which mandates that the Minister for Health and Aged Care seek advice from the Pharmaceutical Benefits Advisory Committee before making such a declaration.

Scope and Application

The National Health Act 1953, under which this Declaration is made, applies broadly to the regulation of health-related matters within the Commonwealth of Australia. The Act encompasses a wide array of health services, including the Pharmaceutical Benefits Scheme, which is a key component in the provision of affordable medication to Australians. The Declaration under subsection 85(2AA) specifically pertains to the cessation of certain drugs and medicinal preparations from being subject to Part VII of the Act, which deals with the listing of drugs on the Pharmaceutical Benefits Scheme. The named drugs and preparations in the Schedule, such as Cilazapril Monohydrate and Diphtheria Vaccine, Adsorbed, will no longer be covered under this part once the Declaration comes into effect on 1 February 1999. This legislative action applies to all individuals and entities within the Australian jurisdiction, effectively removing these specific drugs from the list of subsidised medications available under the Pharmaceutical Benefits Scheme. There are no explicit exclusions or exemptions noted in this particular Declaration, but the scope is limited to the listed drugs and preparations specified in the Schedule. The application of the Act and this Declaration is extended through subordinate instruments, which may further detail the implementation and enforcement of these changes.

Key Provisions

The primary operative sections of the Pharmaceutical Benefits Declaration under Subsection 85 (2AA) of the National Health Act 1953 (subsections 85(2AA) and 85(2AB)) outline the process through which certain drugs and medicinal preparations are removed from the scope of Part VII of the National Health Act 1953. According to section 85(2AA), the Minister for Health and Aged Care can make a declaration, after obtaining advice from the Pharmaceutical Benefits Advisory Committee as mentioned in section 85(2AB). This particular declaration, made by Alan William Stevens on 14 January 1999, specifies that certain drugs and medicinal preparations listed in the attached Schedule will no longer be subject to Part VII of the Act, which governs the Pharmaceutical Benefits Scheme. The obligations imposed by this Act on the parties and entities it governs include the necessity for the Minister for Health and Aged Care to seek advice from the Pharmaceutical Benefits Advisory Committee before making a declaration under section 85(2AA). This advisory process ensures that decisions to remove certain drugs from the Pharmaceutical Benefits Scheme are well-informed and based on expert recommendations. Additionally, the Act mandates that any declaration made must be dated and signed by a designated authority, in this case, Alan William Stevens, Acting Assistant Secretary, Pharmaceutical Benefits Branch, Department of Health and Aged Care, and Delegate of the Minister for Health and Aged Care. In terms of consequences, the Act does not explicitly detail offences, penalties, or civil/criminal consequences for breaches related to the declaration process itself. However, any breach of the National Health Act 1953 or its regulations could lead to enforcement actions under other provisions of the Act. For instance, misleading or deceptive conduct in relation to pharmaceutical benefits could result in penalties under section 118 of the Act, which may include fines of up to $22,000 for individuals and $110,000 for bodies corporate, as well as potential imprisonment terms. The precise penalties for any specific breach would depend on the nature and severity of the contravention, as well as the applicable sections of the Act and any related regulations.